Editas Medicine Stock Today
| EDIT Stock | USD 5.61 0.24 4.10% |
Performance0 of 100
| Odds Of DistressLess than 19
|
Editas Medicine is selling for under 5.61 as of the 18th of April 2024; that is -4.1 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 5.6. Editas Medicine has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Editas Medicine are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of January 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2016 | Category Healthcare | Classification Health Care |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 81.81 M outstanding shares of which 16.36 M shares are currently shorted by private and institutional investors with about 6.85 trading days to cover. More on Editas Medicine
Moving together with Editas Stock
| 0.76 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.72 | GRTX | Galera Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Editas Stock
| 0.61 | MRKR | Marker Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 3rd of May 2024
Editas Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Editas Medicine's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Editas Medicine or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Gilmore MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Editas Medicine report their recommendations after researching Editas Medicine's financial statements, talking to executives and customers, or listening in on Editas Medicine's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Editas Medicine. The Editas consensus assessment is calculated by taking the average forecast from all of the analysts covering Editas Medicine. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the measurements of operating efficiency obtained from Editas Medicine's historical financial statements, Editas Medicine is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Editas Medicine is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Editas Medicine's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Editas Medicine's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Editas Medicine's financial leverage. It provides some insight into what part of Editas Medicine's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Editas Medicine (EDIT) is traded on NASDAQ Exchange in USA. It is located in 11 Hurley Street, Cambridge, MA, United States, 02141 and employs 265 people. Editas Medicine is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 478.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Editas Medicine's market, we take the total number of its shares issued and multiply it by Editas Medicine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Editas Medicine conducts business under Biotechnology sector and is part of Health Care industry. The entity has 81.81 M outstanding shares of which 16.36 M shares are currently shorted by private and institutional investors with about 6.85 trading days to cover.
Editas Medicine currently holds about 452.56 M in cash with (132.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Editas Medicine Probability Of Bankruptcy
Ownership AllocationEditas Medicine holds a total of 81.81 Million outstanding shares. The majority of Editas Medicine outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Editas Medicine to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Editas Medicine. Please pay attention to any change in the institutional holdings of Editas Medicine as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Editas Ownership Details
Editas Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Editas Medicine jumping above the current price in 90 days from now is about 98.0%. The Editas Medicine probability density function shows the probability of Editas Medicine stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.7595 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Editas Medicine will likely underperform. Additionally, editas Medicine has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Editas Medicine to move above the current price in 90 days from now is about 98.0 (This Editas Medicine probability density function shows the probability of Editas Stock to fall within a particular range of prices over 90 days) .
Editas Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Editas Medicine that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Editas Medicine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Editas Medicine's value.| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2023-09-30 | 1.2 M | |
| Credit Suisse First Boston (csfb) | 2023-09-30 | 1.1 M | |
| Two Sigma Advisers, Llc | 2023-09-30 | 1.1 M | |
| Jpmorgan Chase & Co | 2023-09-30 | 1.1 M | |
| Nuveen Asset Management, Llc | 2023-09-30 | 949.1 K | |
| Northern Trust Corp | 2023-09-30 | 888.7 K | |
| Charles Schwab Investment Management Inc | 2023-09-30 | 689 K | |
| D. E. Shaw & Co Lp | 2023-09-30 | 668.7 K | |
| Man Group Plc | 2023-09-30 | 638.2 K | |
| Vanguard Group Inc | 2023-09-30 | 8.5 M | |
| Blackrock Inc | 2023-09-30 | 8.2 M |
Editas Medicine Historical Income Statement
Editas Medicine Income Statement is one of the three primary financial statements used for reporting Editas's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Editas Medicine revenue and expense. Editas Medicine Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Editas Medicine's Total Revenue is comparatively stable compared to the past year. Gross Profit is likely to gain to about 75.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024. View More FundamentalsEditas Stock Against Markets
Picking the right benchmark for Editas Medicine stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Editas Medicine stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Editas Medicine is critical whether you are bullish or bearish towards Editas Medicine at a given time. Please also check how Editas Medicine's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Editas Medicine without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Editas Medicine Corporate Directors
Editas Medicine corporate directors refer to members of an Editas Medicine board of directors. The board of directors generally takes responsibility for the Editas Medicine's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Editas Medicine's board members must vote for the resolution. The Editas Medicine board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Kevin Bitterman | Independent Director | Profile | |
| John Mendlein | Independent Director | Profile | |
| Boris Nikolic | Independent Director | Profile | |
| Douglas Cole | Independent Director | Profile |
How to buy Editas Stock?
Before investing in Editas Medicine, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Editas Medicine. To buy Editas Medicine stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Editas Medicine. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Editas Medicine stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Editas Medicine stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Editas Medicine stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Editas Medicine, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.
Already Invested in Editas Medicine?
The danger of trading Editas Medicine is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Editas Medicine is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Editas Medicine. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Editas Medicine is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Editas Medicine is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Editas Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Editas Medicine Stock. Highlighted below are key reports to facilitate an investment decision about Editas Medicine Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.